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Cultures of human carcinoma A-431, A-549 and HeLa cells were challenged with g-rays without or with concomitant exposure to
gefitinib, a potent inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR). The outcome of treatment was
determined from cell and colony count, cell cycle progression and DNA double-strand break formation and rejoining. Apoptosis was
measured in parallel from hypodiploid DNA and using an annexin V assay. Gefitinib developed a cytostatic effect in all cell lines, with
drug sensitivity correlating the level of EGFR expression. A weak cytotoxicity of gefitinib was observed in HeLa cells only, although the
drug was unable to induce significant cell cycle redistribution in this cell line. In contrast, substantial G1 block and S-phase depletion
was observed in A-431 and A-549 cells exposed to gefitinib. The drug brought about additive to subadditive interaction with
radiation with regard to growth inhibition, clonogenic death and induction of apoptosis. Consistently, gefitinib did not hinder the
rejoining of radiation-induced DNA double-strand breaks in any cell line. The results demonstrate that gefitinib may elicit cytotoxicity
at high concentration, but does not act as a radiosensitiser in vitro in concomitant association with radiation.
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The signalling pathways downstream from the epidermal growth
factor receptor (EGFR) play a key role in the control of tumour cell
proliferation, angiogenesis and metastatic spread. Actually,
activation or overexpression of EGFR has been associated with
local recurrence and poor prognosis in patients (Nicholson et al,
2001; Gupta et al, 2002; Magne ´ et al, 2002), as well as with
resistance to drugs and radiation in murine carcinomas in vivo
(Akimoto et al, 1999) and human tumour cells in vitro (Schmidt-
Ullrich et al, 1997; Dent et al, 1999; Chen et al, 2000). Monoclonal
antibodies such as cetuximab (IMC-225, Imclone or Erbitux), a
human-mouse chimeric antibody directed against the extracellular
ligand-binding region of EGFR, and chemical inhibitors of the
tyrosine kinase domain of EGFR such as gefitinib (‘Iressa’,
ZD1839), a synthetic anilinoquinazoline, have consistently been
designed in hopes that they might downregulate mitogenic
pathways and provide enhanced response to cytotoxic drugs or
ionising radiation.
Preclinical studies of combined treatment with radiation have
been performed with both cetuximab and gefitinib. Enhanced
radiation susceptibility by cetuximab was reported in a variety of
epithelial tumour cell lines in vitro (Huang and Harari, 2000;
Bianco et al, 2002; Culy and Faulds, 2002; Magne ´ et al, 2002;
Williams et al, 2002; Solomon et al, 2003). This effect correlated
increased radiation-induced apoptosis (Huang et al, 1999; Harari
and Huang, 2001; Sclabas et al, 2003) and S-phase depletion
(Huang and Harari, 2000; Harari and Huang, 2001). In combina-
tion with radiation, gefitinib brought on synergistic antiprolifera-
tive and proapoptotic effects in vitro and increased tumour growth
delay in the treatment of human tumour xenografts in mouse
(Bianco et al, 2002; Culy and Faulds, 2002; Huang et al, 2002;
Williams et al, 2002; Solomon et al, 2003).
However, the additivity status of gefitinib–radiation interaction
in vitro has not been firmly established. In fact, the determination
of additivity is subject to many drawbacks, which are listed below.
(i) Contrary to cytotoxic drugs, the equation fitting the dose
dependence of radiation survival includes a quadratic term.
Isobolic methods, based on the isoeffect concept, have been
designed to overcome this difficulty (Steel and Peckham, 1979),
but are not relevant here because the cytotoxicity of EGFR
inhibitors is weak. (ii) Contact with cytostatic agents, such as
EGFR inhibitors, may result in accumulation of cells in a
radiosensitive compartment of the cell cycle (Huang and Harari,
2000). (iii) The presence of cell clusters or multiplets introduces
large errors in viability measurements with clonogenic assays, and
leads to overestimation of radiosensitivity (Rockwell, 1985)
particularly in the low dose range of radiation. This may occur
in experiments involving prolonged exposure to cytostatic drugs as
growth arrest by these drugs is seldom complete. (iv) To overcome
this problem, clusters may be dislocated and replated as isolated
cells. However, immediate plating following radiation allows
expression of the so-called ‘potentially lethal damage’ and boosts
radiation-induced lethality by a large factor (Little et al, 1973).
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y(v) A persistent drop of the proliferation rate is frequently
observed among radiation survivors.
Taking into account the above pitfalls, we re-evaluated the
interaction between gefitinib and radiation in three human tumour
cell lines (A-439, A-541, HeLa) differing in EGFR expression, with
reproductive cell death, altered cell cycle progression and DNA
double-strand break induction and rejoining as end points. The
results show that gefitinib may elicit a cytotoxic potential in some
cell lines but does not impair radiation recovery.
MATERIALS AND METHODS
Products
Gefitinib was kindly provided by AstraZeneca (Rueil-Malmaison,
France) as a micronised powder. Aliquots were stored as a 10mM
stock solution in pure dimethyl sulphoxide (DMSO), and dilutions
were made daily in growth medium. The final concentration of
DMSO (0.2%) was low enough so as not to alter cell growth. Rabbit
polyclonal antibody raised against EGFR came from Cell Signaling
Technology (Beverly, MA, USA). Protease inhibitors and anti-a-
tubulin mouse monoclonal antibody were from Sigma-Aldrich Co.
(Saint Quentin Fallavier, France). Goat HRP-conjugated secondary
antibodies were from Jackson ImmunoResearch Laboratories
(West Grove, PA, USA). All products for cell culture were from
Invitrogen (Cergy-Pontoise, France).
Cell lines
A-431 (human vulvar carcinoma, ATCC CRL-1555; p53 mutated),
A-549 (human lung carcinoma, ATCC CCL-185; wild type p53)
and HeLa cells (human cervix carcinoma, kindly provided by
Dr J Coppey; nonfunctional p53 in relation to HPV16-E6
expression) were grown (371C, 93% air with 7% CO2)a s
monolayers in RPMI-1640 (A-431, A-549) or Dulbecco’s minimal
essential medium (HeLa) supplemented each with 10% foetal calf
serum, 100IUml
 1 penicillin, 0.1mgml
 1 streptomycin and
0.86mgml
 1 Glutamax-I.
A-431 cells reportedly express high levels of EGFR (Ullrich et al,
1984; Christensen et al, 2001; Moasser et al, 2001). Epidermal
growth factor receptor expression is comparatively low in A-549
(Sirotnak et al, 2000; Moasser et al, 2001) and HeLa cells (Hu et al,
1997; Bandyopadhyay et al, 1998). This was confirmed by Western
blot analysis (data not shown) in cells grown under the same
conditions (10% foetal calf serum) as used for gefitinib and
radiation assays. The relative amounts of EGFR were 15.3 (A-431),
1.0 (A-549) and 1.9 (HeLa).
Irradiation
g-Ray irradiation of cells with or without concomitant exposure to
gefitinib was performed at room temperature (21–241C) using an
IBL-637 (
137Cs) irradiator (CIS-Biointernational). The dose rate
was 1.0Gymin
 1.
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Figure 1 Altered cell cycle progression by gefitinib. A-549, A-431 and HeLa cells were exposed to various concentrations of gefitinib for up to 5 days.
Cells were harvested daily after BrdUrd labelling, fixed and analysed by flow cytometry. Sq is the percentage of cells arrested during S phase. The top row
shows the concentration-dependent drug response after 48-h incubation. The bottom row shows the evolution of the various compartments of the cell
cycle in the presence of an IC50 of drug.
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The response of cells to radiation (up to 8Gy), gefitinib (up to
19mM), or a combination of both, was determined using colony-
forming assays. Dimethyl sulphoxide (0.2%) was present at
constant concentration in all experiments. For treatments invol-
ving short drug exposure, 800–1000 cells from exponentially
growing subcultures were isolated by trypsinisation, plated in
triplicate in 25-cm
2 flasks and incubated at 371C for 4h prior to
treatment. Following treatment, the flasks were rinsed twice with
Hank’s balanced salt solution, and cells returned to normal growth
medium for 11 or 12 days. Colonies were fixed with methanol,
stained and scored visually. The surviving fraction was calculated
as the percentage of colonies relative to controls.
As cultures were exposed for 24h or more to gefitinib, cells had to
be plated after treatment. In combined treatment with g-rays, cells
were allowed to recover from radiation for 24h prior to trypsin,
counted and plated at a density of 800–1000 cells (25cm
2 flasks).
For growth inhibition assays, 25cm
2 flasks were seeded with 10
5
cells and incubated for 24h prior to introduction of gefitinib. Cells
were harvested and counted every day for 8 days after drug, with or
without combined irradiation. The drug was renewed every 48h.
Cell cycle analysis
Cell cycle progression was monitored by dual-parameter flow
cytometry using a FACStar PLUS cytofluorometer (Bekton-
Dickinson Biosciences, Le Pont de Claix, France). Cells were
grown for 1–6 days with or without gefitinib. At 20min
before harvesting, cells were incubated with BrdUrd (10mM) for
pulse labelling of S-phase cells. Floating and adherent cells were
pooled after trypsinisation, and fixed in 70% ice-cold ethanol.
Treatment of fixed cells, data acquisition and processing
were performed as described (Demarcq et al, 1992). Cell cycle
analysis was performed with ProCyt software (CEA-INSERM,
Grenoble, France).
DNA double-strand break determination
DNA double-strand breaks were measured by neutral filter elution
as described (Bradley and Kohn, 1979; Pommier et al, 1984). Cells
were labelled with [2-
14C]thymidine (0.06mCiml
 1) for 48h,
allowed to ligate Okasaki fragments prior to treatments and
sequentially lysed by 0.2% N-lauroylsarcosine, 0.2 M NaCl, followed
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Figure 2 Summary of clonogenic radiation response following short (2-h) and prolonged (72-h) contact with gefitinib. For 2-h contact (survival curves),
cells were plated in triplicate before treatment and exposed to gefitinib for 1-h preceding and following irradiation. The surviving fraction (S) was fitted to the
classical linear–quadratic equation, lnS¼ –aD–bD
2, where D is the radiation dose and a and b adjustable parameters. Calculations were made through
nonlinear least-squares regression taking all data points into account, using Kaleidagraph software (Synergy Software, Reading, PA, USA). Bars represent
standard deviation. The dotted lines were drawn according to the linear–quadratic model from the amax, bmax and amin, bmin couples, respectively, and
represent the limit of confidence deduced from standard deviation. For HeLa cells, the minor drop in survival at null radiation dose corresponds to the
cytotoxicity of gefitinib against this cell line. For 72-h contact (bar diagram, bottom right), cells were exposed for 48h to gefitinib, irradiated, incubated with
drug for a further 24h, trypsinised and plated at a suitable density. Survival curves were fitted to the linear–quadratic model. The D37 (or D0) values, that is,
the doses that reduce survival to 1/e¼0.37 of that in controls, were calculated from these curves (see upper left panel). The results suggest a weak trend to
increased radioresistance by gefitinib.
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The retention of [
14C]thymidine-labelled DNA was measured after
20-ml (10-h) elution.
Determination of apoptosis
Apoptosis was determined on floating and adherent cells using two
techniques.
(i) Analysis of DNA fragmentation by flow cytometry: The
hypodiploid (sub-G1) fraction was measured using FACS
analysis of propidium-iodide-stained cells after overnight
fixation with cold 70% ethanol. The sub-G1 region was
determined by a gate on the DNA content histogram
excluding the debris at the origin of the abscissa.
(ii) Annexin V assay: Detection of phosphatidylserine on the
outer face of the plasma membrane was carried out on fresh
cells with FITC-conjugated Annexin V (Oncogene Research
Products, San Diego, CA, USA). 10
6 cells were suspended in
1ml ice-cold binding buffer (10mM HEPES, 150mM NaCl,
2.5mM CaCl2,1m M MgCl2, 4% BSA, pH 7.4). A volume of 10ml
of media-binding buffer and 1.25ml of Annexin V-FITC
(200mgml
 1) were added to 500ml of the cell suspension for
15min at room temperature, in the dark. Cells were harvested
by centrifugation and resuspended in 0.5ml cold binding
buffer. A first analysis by flow cytometry was immediately
performed with cells stained with Annexin V-FITC only.
Propidium iodide (10ml; 30mgml
 1 in PBS) was subsequently
added and analysis of both PI and FITC fluorescence was
carried out with CellQuest Pro software (Becton-Dickinson
Biosciences) as described (Darzynkiewicz et al, 1997). Cells
that bound Annexin V-FITC without propidium iodide
staining were considered as early apoptotic cells; necrotic or
apoptotic cells in terminal stages were positive for both
annexin V-FITC and propidium iodide.
Western blot analysis
2 10
7 mid-log growing cells were lysed in 250ml RIPA buffer
supplemented with 1mM phenylmethanesulphonyl fluoride plus
protease inhibitors. Proteins were titrated using the Bio-Rad’s DC
protein assay (Bio-Rad, Hercules, CA, USA). After SDS–poly-
acrylamide gel electrophoresis, the proteins were blotted onto
nitrocellulose membrane (Scleicher & Schuell, Dassel, Germany),
incubated with specific primary and secondary antibodies and
revealed using an ECL kit. The densitometric analysis of films was
carried out with the aid of QuantityOne software (Bio-Rad).
RESULTS
Growth inhibition and cell cycle redistribution by gefitinib
Cells were incubated in the presence of increasing concentrations
of gefitinib for up to 8 days, and growth measured by cell count
relative to untreated samples. Gefitinib alone produced a
concentration-dependent inhibition of cell proliferation in the
three cell lines. IC50, that is, the drug concentration that reduced
growth to 50% of that in controls (5-days contact with drug) was
0.3, 6 and 8mM for A-431, A-549 and HeLa cells, respectively.
Cell cycle disruption by gefitinib was investigated by flow
cytometry as a function of both the drug concentration and length
of incubation. Gefitinib brought about G1-phase accumulation and
S-phase depletion in A-549 and A-431 cells only (Figure 1). Above
the IC50, the strength of this effect depended more on the length of
contact with the drug than on the drug concentration, and was as
anticipated from earlier studies (Bianco et al, 2002; Huang et al,
2002; Solomon et al, 2003). In addition, substantial accumulation
of hypodiploid (sub-G1) nuclei was observed specifically in A-431
cells in proportion to the drug concentration and the length of
incubation (see below). Minor amounts of hypodiploid nuclei were
also observed in HeLa cells, although gefitinib did not perturb cell
cycle progression in this cell line.
Cytotoxicity of gefitinib and phenotype alteration
The cytotoxic potential of gefitinib in short exposure (2-h), was
assessed by clonogenic assays in the three cell lines of interest. No
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Figure 3 Growth inhibition by gefitinib and radiation. Cells were
exposed to gefitinib for 48h, irradiated and subsequently incubated with
gefitinib for up to 7 days. Note that radiation survivors did not recover a full
growth potential. Gefitinib induced an additional cytostatic effect, in such a
way that growth curves with and without drug were parallel.
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gefitinib developed weak, concentration-dependent cytotoxicity
(IC50E51mM) against HeLa cells.
Prolonged contact with gefitinib at high concentration resulted
in marked alterations in cell morphology. Cells flattened with an
increased cytoplasm-to-nucleus surface ratio by a factor of
2.070.3, and A-549 and A-431 cells at the periphery of colonies
extended large lamellipodes. This might explain why, in a few
instances, a substantial part of cells was killed by trypsin after
prolonged exposure to gefitinib.
Effect of gefitinib on radiation survival: clonogenic assays
To determine whether gefitinib was able to alter radiation survival,
cells were exposed to gefitinib for 1h, irradiated and returned to
the incubator for a further 1h in the presence of drug. No
modification of radiation response was observed in any of the
three cell lines (Figure 2).
A different protocol was used to study the effect of prolonged
contact (424h) with gefitinib. In that case, cells were trypsinised
and plated at a known density long enough after irradiation (24h)
to allow the repair of potentially lethal damage. No significant
difference was observed between radiation alone and combined
treatment, though a trend towards a minor increase of radio-
resistance was noted (Figure 2). Finally, no change in radio-
sensitivity was observed as the length of drug contact preceding
and following irradiation was raised from 1 to 48h.
Effect of gefitinib on radiation survival: growth inhibition
Plated cells were allowed to grow for 24h, then incubated for 48h
with gefitinib, irradiated and harvested after an additional 1–6-
days incubation in the presence of gefitinib at the same
concentration. The cell count was monitored daily.
Figure 3 shows the results from cells exposed to an IC50 of
gefitinib. Gefitinib exerted a cytostatic effect, as expected.
Persistent attrition of the reproductive potential, in addition to
induced kill, was observed in irradiated cells. This, notwithstand-
ing cell proliferation relative to control in combined treatment,
matched exactly the product of the growth-inhibitory effects of
radiation and gefitinib applied independently, indicating strict
additivity (Table 1).
Effect of gefitinib on DNA double-strand break induction
or repair
Epidermal growth factor receptor-dependent transduction has
been reported to generate activation, enhance transcription and
nuclear translocation of DNA-dependent protein kinase (DNA-PK)
in A-431, HeLa and SCC-13Y cells (Bandyopadhyay et al, 1998;
Huang et al, 2002). Cetuximab has also been reported to trigger
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Figure 4 Neutral elution analysis of DNA double-strand break
formation and repair after exposure to gefitinib (3-h contact), irradiation
(30Gy) or a combination of both. In combined treatment, cells were
exposed to gefitinib for 2h, irradiated and lysed immediately or after 1-h
recovery at 371C. Each experiment was performed in duplicate. Bars, mean
deviation.
Table 1 Cell proliferation relative to control for gefitinib, radiation or a
combination of both
Treatment A-431 A-549 HeLa
a Gefitinib 0.253 (0.3mM) 0.343 (6mM) 0.470 (8mM)
b Radiation (5Gy) 0.473 0.538 0.161
c Product a b 0.120 0.184 0.076
d Combined treatment 0.119 0.192 0.082
Treatments were as in Figure 4, and cells were counted at day 7 after the beginning of
treatment.
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Figure 5 Flow cytometric analysis of the hypodiploid (sub-G1) DNA
content in A-431 and HeLa cells exposed to gefitinib, radiation or a
combination of both. Cells were exposed to gefitinib for 60h, irradiated,
returned to the incubator in the presence of gefitinib and collected at the
times indicated. Mock-irradiated samples were collected after the same
length of incubation.
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cytoplasmic fraction and deplete the nuclear pool of DNA–PK
(Bandyopadhyay et al, 1998). Whether this elicits impaired DSB
repair and increased radiation susceptibility in vivo is open to
question, as phase I studies did not show limiting toxicity of
cetuximab in association with radiotherapy against advanced head
and neck cancer (Robert et al, 2001). It may be best to consider
that nuclear exclusion of DNA-PK results from S-phase depletion
by the antibody. Actually, cetuximab causes a marked G1 block
(Huang and Harari, 2000), while nuclear import and activation of
DNA-PKcs occur only in S phase and at the G1/S junction (Lee
et al, 1997; Nilsson et al, 1999). Gefitinib might induce the same
effect.) As DNA-PK plays a key role in DNA double-strand break
repair through NHEJ, the effect of gefitinib on the rejoining of
radiation-induced breaks was investigated by neutral filter elution.
Gefitinib alone did not induce any DNA damage. When tested in
A-431 and HeLa cells, gefitinib had no effect on the incidence or
rejoining of DNA double-strand breaks (Figure 4).
Apoptosis in combined treatment with radiation and
gefitinib
Apoptosis by gefitinib without and with combined exposure to
radiation was investigated in the three cell lines. No apoptosis was
detected in A-549 cells, confirming that A-549 cells are resistant to
this mode of cell death (Lawrence et al, 2001; Stuschke et al, 2002).
Therefore, the results presented below are for A-431 and HeLa cells
only. Two methods were used to assess apoptosis. In each instance,
cells were pre-incubated for 48h with an IC50 of gefitinib, prior to
g-ray irradiation. Irradiated cells were collected after a further 24-,
48- or 72-h incubation, long after completion of DNA repair.
(i) Gefitinib generated hypodiploid (sub-G1) nuclei in A-431 and
HeLa cells, though to a much lower extent in the latter.
Ionising radiation also induced an increase of the sub-G1
fraction. In both cell lines, combined treatment produced
additive interaction at 24h. In contrast, infra-additive
interaction was observed at 48 and 72h of post-irradiation
incubation in both cell lines (Figure 5).
(ii) FACS analysis of annexin V-FITC binding to the cells’ plasma
membrane correlated with the sub-G1 content (Figure 6).
Gefitinib alone induced significant apoptosis above background
in A-431 cells only. Radiation-induced apoptosis was observed
in both A-431 and HeLa cells, but combined treatment did not
promote apoptosis. In A-431 cells, nearly additive interaction
was observed at 24h, but infra-additive interaction occurred at
48 and 72h of post-irradiation incubation in both cell lines.
DISCUSSION
We found that short (2-h) exposure to gefitinib had no effect on
radiation response in clonogenic assays, and strictly additive
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Figure 6 Annexin V-FITC analysis of apoptosis in A-431 and HeLa cells. Cells were exposed to gefitinib for 60h, irradiated, returned to the incubator in
the presence of gefitinib and collected at the times indicated. Nonirradiated, drug-free controls were collected after the same length of incubation. The
distinction between early and late apoptosis was made as described (Darzynkiewicz et al, 1997).
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gefitinib. Consistently, gefitinib did not impair DNA double-strand
break rejoining (Figure 4) and did not interfere with the radiation-
induced G2-M block (data not shown). In our hands, gefitinib and
radiation acted additively to induce apoptosis in A-431 and HeLa
cells after 24-h contact with drug, whereas the interaction was
infra-additive (possibly antagonistic) after more prolonged ex-
posure (Figures 5 and 6). However, significant amounts of
gefitinib-induced apoptosis were observed in A-431 cells only. In
spite of the fact that HeLa cells elicited cytotoxic response to
gefitinib, drug-induced apoptosis in HeLa cells was below 5%; A-
549 cells did not show evidence of apoptosis. Accordingly, the
apoptotic potential and the growth-inhibitory efficiency of
gefitinib are not inter-related in the three cell lines used.
HeLa cells did not show significant cell cycle redistribution by
gefitinib. In contrast, and in agreement with others (Bianco et al,
2002; Huang et al, 2002; Williams et al, 2002), we observed that in
A-431 and A-549 cells gefitinib induced accumulation in G1 at the
expense of S phase. Moreover, radiation potentiated growth arrest
by the drug (Figures 1 and 4). S phase has long been known to be
the most radioresistant compartment of the cell cycle (Terasima
and Tolmach, 1963). Therefore, as pointed out by Huang
and Harari (2000), S-phase depletion by gefitinib could even-
tually lead to increased radiosensitivity in cells responding to
gefitinib. Indirect evidence in favor of this scheme was provided
by Wollman et al (1994), who showed that stimulation of MCF-7
cells by extraneously added EGF produced a substantial
increase in both S-phase content and radioresistance. However,
despite significant S-phase depletion in A-431 and A-549 cells
(Figure 1), no radiosensitisation was observed after 72-h contact
with gefitinib (Figure 3).
In conclusion, gefitinib at cytostatic concentration did not
impair the rejoining of radiation-induced DNA double-strand
breaks, and brought about additive interaction with radiation in
terms of growth inhibition or induced cell death in A-431, A-549
and HeLa cells. Such additivity may be beneficial in chemo-
radiotherapeutic combination. Indeed, supra-additive interaction
may lead to acute hypertoxicity, reduction of the maximum
tolerated doses of both drug and radiation and treatment failure.
Contrary to a widely held opinion, radiosensitisation should be
considered with care when it comes to eliciting inhibition of
radiation recovery (Balosso et al, 1995). Well-known examples of
limiting toxicities are from adriamycin (Mayer et al, 1976) and
bleomycin (Peters et al, 1988).
It should be recalled here that the most useful mechanisms in
chemo-radiotherapeutic combinations are spatial cooperation,
reoxygenation and inhibition of tumour repopulation. Reduction
in tumour volume after chemotherapy, when it occurs, may result
in improved blood supply to the tumour, leading to reoxygenation
and increased radiosensitivity. Furthermore, inhibition of neoan-
giogenesis may lead to increased radiocurability (Brown, 2001;
Hennequin and Favaudon, 2002), and in fact recent studies
have convincingly shown that both cetuximab and gefitinib are
able to afford potentiation of radiotherapy and inhibition of
neoangiogenesis in human tumour xenografts in mice (Bianco et al,
2000, 2002; Huang and Harari, 2000; Milas et al, 2000; Buchsbaum
et al, 2002; Huang et al, 2002; Williams et al, 2002). This might
allow gefitinib and radiotherapy to be used concomitantly or in
close temporal proximity to take advantage of inhibition of tumour
neoangiogenesis or altered cell cycle distribution, without the
acute or late healthy tissue complications that are at risk with
inhibition of DNA repair.
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